SEELOS THERAPEUTICS INC's ticker is SEEL and the CUSIP is 81577F109. A total of 93 filers reported holding SEELOS THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.18 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $91,518 | -79.9% | 497,380 | +30.6% | 0.00% | – |
| Q2 2023 | $455,139 | +88.5% | 380,869 | +9.0% | 0.00% | – |
| Q1 2023 | $241,503 | +1.2% | 349,398 | -0.6% | 0.00% | – |
| Q4 2022 | $238,556 | -27.9% | 351,335 | +9.4% | 0.00% | – |
| Q3 2022 | $331,000 | +28.3% | 321,249 | -15.4% | 0.00% | – |
| Q2 2022 | $258,000 | -16.5% | 379,560 | +2.9% | 0.00% | – |
| Q1 2022 | $309,000 | -44.3% | 368,777 | +8.3% | 0.00% | – |
| Q4 2021 | $555,000 | +70.8% | 340,595 | +152.6% | 0.00% | – |
| Q3 2021 | $325,000 | -87.2% | 134,812 | -86.0% | 0.00% | – |
| Q2 2021 | $2,539,000 | +5804.7% | 961,923 | +11056.6% | 0.00% | – |
| Q1 2021 | $43,000 | +616.7% | 8,622 | +115.6% | 0.00% | – |
| Q4 2020 | $6,000 | -33.3% | 4,000 | -60.0% | 0.00% | – |
| Q3 2020 | $9,000 | -10.0% | 10,000 | 0.0% | 0.00% | – |
| Q2 2020 | $10,000 | – | 10,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 2,500,000 | $4,075,000 | 1.71% |
| Connacht Asset Management LP | 498,925 | $813,000 | 0.79% |
| GENDELL JEFFREY L | 2,449,267 | $3,992,000 | 0.32% |
| MANGROVE PARTNERS IM, LLC | 2,133,436 | $3,478,000 | 0.21% |
| Uniplan Investment Counsel, Inc. | 1,550,359 | $2,527,000 | 0.14% |
| Financial Advocates Investment Management | 24,673 | $1,994,000 | 0.13% |
| Connacht Asset Management LP | 72,300 | $118,000 | 0.12% |
| Woodline Partners LP | 4,047,231 | $6,597,000 | 0.09% |
| 1492 Capital Management LLC | 108,286 | $177,000 | 0.09% |
| Ikarian Capital, LLC | 244,171 | $398,000 | 0.06% |